Clinical Trial
Share your love
Foundation Fighting Blindness releases 4-year RUSH2A data to public | Ophthalmology Times
(Image Credit: AdobeStock/Ar_TH) Foundation Fighting Blindness has granted public access to de-identified 4-year data from individuals participating in RUSH2A, an ongoing natural history study for patients with mutations in the USH2A gene, which causes Usher syndrome type 2A or nonsyndromic retinitis pigmentosa…
Opus Genetics doses first patient in phase 1/2 clinical trial, BIRD-1, evaluating OPGx-BEST1 | Ophthalmology Times
(Image Credit: AdobeStock/Treecha) Opus Genetics has dosed the first patient in its OPGx-BEST1 phase 1/2 clinical trial, BIRD-1, for Best disease (BEST1). Best disease, also known as vitelliform macular dystrophy, is a rare, inherited retinal condition causing macular degeneration by…
Understanding Tear Composition and Function in Dry Eye Disease | Ophthalmology Times
The Viewpoints series “Reimagining Dry Eye Management: Targeting Tear Function for Sustained Relief” convenes leading experts in ophthalmology and optometry to discuss evolving perspectives on dry eye disease (DED). Under the moderation of Kendall Donaldson, MD, MS, the panel—comprising Cecelia…
Identification and Diagnosis of Dry Eye Disease | Ophthalmology Times
The Viewpoints series “Reimagining Dry Eye Management: Targeting Tear Function for Sustained Relief” convenes leading experts in ophthalmology and optometry to discuss evolving perspectives on dry eye disease (DED). Under the moderation of Kendall Donaldson, MD, MS, the panel—comprising Cecelia…
LASIK and beyond: Navigating the changing landscape of refractive surgery | Ophthalmology Times
Ophthalmologists share how emerging LASIK techniques and technologies are improving outcomes and shaping the future of refractive surgery. (Image credit: AdobeStock/rohane) Refractive surgery continues to transform, with innovations in LASIK and other vision-correction procedures improving precision and patient outcomes. The…
SparingVision doses first patient in NYRVANA clinical trial of SPVN20 for retinitis pigmentosa | Ophthalmology Times
(Image Credit: AdobeStock/Davizro Photography) SparingVision has dosed the first patient in its NYRVANA clinical trial of SPVN20 in patients with advanced retinitis pigmentosa (RP). NYRVANA is the first-in-human trial and is an open-label, multicenter, dose-escalation study investigating the safety, tolerability,…
Eli Lilly to acquire Adverum Biotechnologies | Ophthalmology Times
Image credit: AdobeStock/jozefmicic The Eli Lilly and Company will acquire Adverum Biotechnologies, according to a joint press release issued by the 2 companies. The companies noted that this definitive agreement will include Adverum’s lead candidate, Ixo-vec. Adverum and Lilly’s merger…
Positive phase 2 data for neoadjuvant darovasertib offers hope for unmet need in uveal melanoma | Ophthalmology Times
Image credit: AdobeStock/Christoph Burgstedt Positive results from the ongoing Phase 2 OptimUM-09 trial are encouraging for the treatment of uveal melanoma (UM). According to the press release from IDEAYA Biosciences, the developers of this therapeutic candidate, “there are currently no…
The future of glaucoma care: Where innovation meets everyday practice | Ophthalmology Times
Specialists in glaucoma care share insights on evolving strategies, technologies, and treatments shaping the future of patient management. (Image credit: AdobeStock) As glaucoma care continues to advance, ophthalmologists are embracing innovative technologies and new approaches that are reshaping diagnosis and…
New data from Sweden highlight lesion features that accelerate GA growth | Ophthalmology Times
(Image Credit: AdobeStock/Alexey Novikov) The lesion characteristics of patients with geographic atrophy (GA) were found to affect the lesion growth rate, with fovea-sparing, multifocal, and bilateral lesions having the fastest growth rates in a study published in Translational Vision Science…